1. Home
  2. ZIP vs RAPP Comparison

ZIP vs RAPP Comparison

Compare ZIP & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ZipRecruiter Inc.

ZIP

ZipRecruiter Inc.

HOLD

Current Price

$3.36

Market Cap

295.1M

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$34.85

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZIP
RAPP
Founded
2010
2022
Country
United States
United States
Employees
N/A
84
Industry
Diversified Commercial Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
295.1M
1.8B
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
ZIP
RAPP
Price
$3.36
$34.85
Analyst Decision
Hold
Strong Buy
Analyst Count
4
6
Target Price
$3.88
$48.50
AVG Volume (30 Days)
803.6K
292.6K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
24.34
EPS
N/A
N/A
Revenue
$448,952,000.00
N/A
Revenue This Year
$1.00
N/A
Revenue Next Year
$5.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.65
$7.73
52 Week High
$6.55
$42.27

Technical Indicators

Market Signals
Indicator
ZIP
RAPP
Relative Strength Index (RSI) 56.99 48.69
Support Level $3.35 $25.48
Resistance Level $5.45 $41.33
Average True Range (ATR) 0.36 2.54
MACD -0.03 -0.42
Stochastic Oscillator 41.73 30.65

Price Performance

Historical Comparison
ZIP
RAPP

About ZIP ZipRecruiter Inc.

ZipRecruiter Inc is an online employment marketplace that connects job seekers and employers through an AI-powered platform. The company provides recruiting solutions that help employers identify and hire qualified candidates while enabling job seekers to discover relevant job opportunities through intelligent matching and recommendation tools.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: